Bevacizumab and Sinus Venous Thrombosis: A Literature Review.
| Autor: | Jaiswal V; Research and Academic Affairs, Larkin Community Hospital, South Miami, USA., Jain E; Medicine, American University of Antigua, St. John's, ATG., Hitawala G; Internal Medicine, JC Medical Center, Orlando, USA., Loh H; Medicine, National University of Singapore, Singapore, SGP., Patel S; Medicine, B J Medical College, Ahmedabad, IND., Thada P; Research, Larkin Community Hospital, South Miami, USA., Nandwana V; Medicine, Lady Hardinge Medical College, Delhi, IND., Pandey S; Research, Larkin Community Hospital, South Miami, USA., Quinonez J; Neurology/Osteopathic Neuromuscular Medicine, Larkin Community Hospital, South Miami, USA., Naz S; Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA., Stein JD; Osteopathic Neuromusculoskeletal Manipulative Medicine, Family Medicine, Sports Medicine, Pain Medicine, Lake Erie College of Osteopathic Medicine Bradenton, Bradenton, USA.; Pain Mangement, Osteopathic Neuromusculoskeletal Manipulative Medicine, Sports Medicine, Larkin Community Hospital, South Miami, USA., Cueva W; Neurology, Larkin Community Hospital, South Miami, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2021 Nov 11; Vol. 13 (11), pp. e19471. Date of Electronic Publication: 2021 Nov 11 (Print Publication: 2021). |
| DOI: | 10.7759/cureus.19471 |
| Abstrakt: | Pediatric glioma treatment can be confounded by eloquent anatomical location and pathologic and genetic characteristics. Current literature suggests that the vascular endothelial growth factor (VEGF) inhibitor bevacizumab has been linked to enhancing disease control; however, its safety and effectiveness are unknown. Bevacizumab has been linked with an increased incidence of intratumoral hemorrhage as well as arterial and venous thromboembolism. A rare adverse effect of chemotherapeutic treatment with bevacizumab is sinus venous thrombosis (SVT), with only a few cases reported to date. This review highlights the pathophysiology of bevacizumab, its rare and life-threatening side effect of SVT, and future recommendations. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Jaiswal et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|